LON:AGY - Allergy Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 27.75 0.00 (0.00 %)
(As of 07/18/2018 02:22 PM ET)
Previous CloseGBX 27.75
Today's RangeGBX 27 - GBX 28.15
52-Week RangeGBX 23 - GBX 39.50
Volume44,618 shs
Average Volume167,682 shs
Market Capitalization£144.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Allergy Therapeutics logoAllergy Therapeutics plc, a specialty pharmaceutical company, focuses on allergy vaccination primarily in Europe. The company's primary flagship product is the Pollinex Quattro for the treatment of allergic conditions. It offers monophosphoryl-lipid A, a substance that enhances the immune response to an antigen or allergen; sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; and synbiotics that are special formulations of prebiotics and probiotics, such as Kallergen-Th, ATI Prob, and Pollagen. The company also provides Acarovac Plus, a novel microcrystalline tyrosine adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzyl penicillin and related antibiotics (beta lactams) by means of cutaneous tests (prick and intradermal). In addition, it develops products based on synbiotics that are Kallergen Th and SynGut; Acarovac Plus and Acarovac MPL that are next generation products for dust mite immunotherapy; Polyvac, a peanut vaccine; and G204, G205, and G306, as well as PQBirch 301 and PQBirch 204 that are subcutaneous immunotherapies, which are in various development phases. The company markets its products in injectable and sublingual formats under various brands. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.

Receive AGY News and Ratings via Email

Sign-up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolLON:AGY
CUSIPN/A
Phone+44-1903-844700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins14.27%
Return on Equity36.50%
Return on Assets19.69%

Miscellaneous

EmployeesN/A
Outstanding Shares603,970,000
Market Cap£144.63

The Truth About Cryptocurrencies

Allergy Therapeutics (LON:AGY) Frequently Asked Questions

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

What price target have analysts set for AGY?

2 Wall Street analysts have issued 12 month price objectives for Allergy Therapeutics' shares. Their predictions range from GBX 45 to GBX 47. On average, they expect Allergy Therapeutics' stock price to reach GBX 46 in the next year. This suggests a possible upside of 65.8% from the stock's current price. View Analyst Ratings for Allergy Therapeutics.

What is the consensus analysts' recommendation for Allergy Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergy Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Allergy Therapeutics' key competitors?

Who are Allergy Therapeutics' key executives?

Allergy Therapeutics' management team includes the folowing people:
  • Mr. Manuel Llobet, CEO & Exec. Director (Age 54)
  • Mr. Nicolas Alexander Ulrich Wykeman, Fin. Director & Exec. Director (Age 53)
  • Ms. Beverly Lees, Operations Director
  • Dr. Murray Skinner, Chief Scientific Officer
  • Mr. Santiago Puig, Bus. Devel. Director

Has Allergy Therapeutics been receiving favorable news coverage?

Press coverage about AGY stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Allergy Therapeutics earned a daily sentiment score of 0.16 on Accern's scale. They also gave media headlines about the company an impact score of 46.60 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Allergy Therapeutics?

Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Allergy Therapeutics' stock price today?

One share of AGY stock can currently be purchased for approximately GBX 27.75.

How big of a company is Allergy Therapeutics?

Allergy Therapeutics has a market capitalization of £144.63 million.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700.


MarketBeat Community Rating for Allergy Therapeutics (LON AGY)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  382
MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics and other stocks. Vote "Outperform" if you believe AGY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.